Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers C > Headlines for Codiak BioSciences, Inc. > News item |
Codiak BioSciences reports $40.78 million net loss for May
By Sarah Lizee
Olympia, Wash., June 20 – Codiak BioSciences, Inc. reported a $40.78 million net loss for May on zero gross income or sales, according to its monthly operating report filed Friday with the U.S. Bankruptcy Court for the District of Delaware.
The company listed $4.34 million in selling expenses, $5.23 million in general and administrative expenses, and $31 million in other expenses.
The cash balance at the end of the month was $11.99 million.
Codiak BioSciences is a clinical-stage biopharmaceutical company based in Cambridge, Mass. The company filed bankruptcy on March 27 under Chapter 11 case number 23-10350.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.